Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00214318
Status:
COMPLETED
Last Update Posted:
2015-10-08
First Post:
2005-09-14
Brief Title:
Beta-2 Polymorphisms and Beta Receptor Selectivity
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
The Effects of ß2 Polymorphisms on Beta Selectivity After ß-adrenergic Blockade in Patients With Heart Failure
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent b-2 polymorphisms may contribute to differing responses to drug treatment with beta-blockers in heart failure Characterizing these polymorphisms may help explain the variability in the degree of selectivity of action of b-blockers at the b receptor namely if their action is specific for the b-1 or b-2 receptor Part A was conducted at the University of Utah and all subjects completed study related activities Part B sub-study consists of genotyping of blood samples collected in part A which will be completed at the University of Wisconsin Sub-study samples and DNA isolation or Part B entailed analyzing an extra 10 mL of blood that was taken for DNA isolation Genotyping ie determination of genetic makeup of beta adrenergic polymorphisms utilized polymerase chain reaction followed by pyrosequencing
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None